Literature DB >> 19610059

Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines.

Shailesh Singh1, Rajesh Singh, Udai P Singh, Shesh N Rai, Kristian R Novakovic, Leland W K Chung, Peter J Didier, William E Grizzle, James W Lillard.   

Abstract

Chemokines and chemokine receptors have been shown to be involved in metastatic process of prostate cancer (PCa). In this study, we show primary PCa tissues and cell lines (LNCaP and PC3) express CXCR5, a specific chemokine receptor for CXCL13. Expression of CXCR5 was significantly higher (p < 0.001) in PCa cases than compared to normal match (NM) tissues. CXCR5 intensity correlated (R(2) = 0.97) with Gleason score. While prostate tumor tissues with Gleason scores >or= 7, displayed predominantly nuclear CXCR5 expression patterns, PCa specimens with Gleason scores <or= 6 showed predominantly membrane and cytoplasmic expression patterns that were comparable to benign prostatic hyperplasia (BPH). Similar to tissue expression, PCa cell lines expressed significantly more CXCR5 than normal prostatic epithelial cells (PrECs), and CXCR5 expression was distributed among intracellular and extracellular compartments. Functional in vitro assays showed higher migratory and invasive potentials toward CXCL13, an effect that was mediated by CXCR5. In both PCa cell lines, CXCL13 treatment increased the expression of collagenase-1 or matrix metalloproteinase-1 (MMP-1), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10) and stromelysin-3 (MMP-11). These data demonstrate the clinical and biological relevance of the CXCL13-CXCR5 pathway and its role in PCa cell invasion and migration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19610059      PMCID: PMC3600527          DOI: 10.1002/ijc.24574

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

1.  MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues.

Authors:  B Birkedal-Hansen; Z P Pavelic; J L Gluckman; P Stambrook; Y Q Li; W G Stetler-Stevenson
Journal:  Oral Dis       Date:  2000-11       Impact factor: 3.511

2.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

3.  Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue.

Authors:  K Still; C N Robson; P Autzen; M C Robinson; F C Hamdy
Journal:  Prostate       Date:  2000-01       Impact factor: 4.104

Review 4.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

Review 5.  Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues.

Authors:  Lisa M Ebert; Patrick Schaerli; Bernhard Moser
Journal:  Mol Immunol       Date:  2004-11-23       Impact factor: 4.407

6.  Stromal cells in lymph nodes attract B-lymphoma cells via production of stromal cell-derived factor-1.

Authors:  J Arai; M Yasukawa; Y Yakushijin; T Miyazaki; S Fujita
Journal:  Eur J Haematol       Date:  2000-05       Impact factor: 2.997

7.  Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer.

Authors:  S U Woo; J W Bae; H G Kim; S H Choi; D H Kang; J B Lee; B W Koo
Journal:  J Int Med Res       Date:  2007 Nov-Dec       Impact factor: 1.671

8.  CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.

Authors:  Shailesh Singh; Udai P Singh; William E Grizzle; James W Lillard
Journal:  Lab Invest       Date:  2004-12       Impact factor: 5.662

9.  CD4+CD3- cells induce Peyer's patch development: role of alpha4beta1 integrin activation by CXCR5.

Authors:  D Finke; H Acha-Orbea; A Mattis; M Lipp; J Kraehenbuhl
Journal:  Immunity       Date:  2002-09       Impact factor: 31.745

10.  Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.

Authors:  G I Murray; M E Duncan; P O'Neil; J A McKay; W T Melvin; J E Fothergill
Journal:  J Pathol       Date:  1998-07       Impact factor: 7.996

View more
  37 in total

1.  Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer.

Authors:  Shi-Liang Gui; Li-Chen Teng; Shu-Qiu Wang; Shuang Liu; Ying-Li Lin; Xiao-Lian Zhao; Lei Liu; Hong-Yu Sui; Yang Yang; Li-Chun Liang; Mo-Lin Wang; Xin-Yi Li; Yu Cao; Feng-Ying Li; Wei-Qun Wang
Journal:  Int Urol Nephrol       Date:  2016-02-02       Impact factor: 2.370

2.  Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway.

Authors:  Rachana Garg; Jorge M Blando; Carlos J Perez; Martin C Abba; Fernando Benavides; Marcelo G Kazanietz
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

3.  Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.

Authors:  Shailesh Singh; Rajesh Singh; Praveen K Sharma; Udai P Singh; Shesh N Rai; Leland W K Chung; Carlton R Cooper; Kristian R Novakovic; William E Grizzle; James W Lillard
Journal:  Cancer Lett       Date:  2009-04-17       Impact factor: 8.679

4.  Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts.

Authors:  Massimo Ammirante; Shabnam Shalapour; Youngjin Kang; Christina A M Jamieson; Michael Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

5.  CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway.

Authors:  Zhenyu Zhu; Xukui Zhang; Hongliang Guo; Ling Fu; Ganlin Pan; Yinggang Sun
Journal:  Mol Cell Biochem       Date:  2014-12-05       Impact factor: 3.396

6.  Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors.

Authors:  Hina Mir; Neeraj Kapur; Rajesh Singh; Guru Sonpavde; James W Lillard; Shailesh Singh
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

7.  CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation.

Authors:  C P El-Haibi; R Singh; P K Sharma; S Singh; J W Lillard
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

8.  Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer.

Authors:  Christelle P El-Haibi; Rajesh Singh; Pranav Gupta; Praveen K Sharma; Krysta N Greenleaf; Shailesh Singh; James W Lillard
Journal:  J Proteomics Bioinform       Date:  2012

9.  PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells.

Authors:  Christelle P El Haibi; Praveen K Sharma; Rajesh Singh; Paul R Johnson; Jill Suttles; Shailesh Singh; James W Lillard
Journal:  Mol Cancer       Date:  2010-04-22       Impact factor: 27.401

Review 10.  Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment.

Authors:  Aliyah M Weinstein; Walter J Storkus
Journal:  Adv Cancer Res       Date:  2015-05-05       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.